Technology | April 14, 2010

ProxiScan


April 14, 2010 - For the first time, the U.S. Food and Drug Administration (FDA) gave 510(k) clearance to a gamma camera indicated for endocavity imaging.

The technology is designed to address a widespread need for higher quality nuclear-medical images for prostate cancer diagnosis. ProxiScan is a small cadmium zinc telluride (CZT)-based compact gamma camera developed by Hybridyne in collaboration with scientists at Brookhaven National Laboratory.

The system can be used in imaging the distribution of radionuclides in the human body, using planar imaging techniques. The system may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used. ProxiScan is also capable of imaging radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head.

For more information: www.hybridyneimagingtechnologies.com


Additional Content

News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
News | Radiation Therapy

January 19, 2024 — Treating tumors is a global health issue. In radiotherapy, radiation is used to destroy tumor cells ...

Time January 19, 2024
arrow
Feature | PET Imaging

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

Time September 05, 2023
arrow
News | Radiology Imaging

August 24, 2023 — Medical imaging via X-rays, CT scans, MRIs and ultrasounds provide health-care professionals with ...

Time August 24, 2023
arrow
Subscribe Now